Standout Papers
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial (2009)
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study (2012)
- B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial (2022)
Immediate Impact
5 from Science/Nature 56 standout
Citing Papers
Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Works of Paul Brunetta being referenced
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
2012 Standout
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Paul Brunetta | 2478 | 567 | 662 | 1664 | 1176 | 30 | 3.5k | |
| Kevin Latinis | 2069 | 274 | 438 | 1870 | 1257 | 21 | 3.9k | |
| Cheryl Yarboro | 3192 | 242 | 721 | 2521 | 828 | 51 | 5.2k | |
| Barri J. Fessler | 3576 | 390 | 397 | 2261 | 667 | 63 | 5.3k | |
| W. Joseph McCune | 3494 | 688 | 256 | 3055 | 866 | 97 | 6.0k | |
| Romeo Maciuca | 1529 | 263 | 342 | 1244 | 737 | 25 | 2.4k | |
| Holly M. Bastian | 3221 | 142 | 370 | 2035 | 661 | 41 | 3.9k | |
| Graham Hughes | 2748 | 250 | 407 | 1590 | 603 | 48 | 3.7k | |
| Jorge Sánchez‐Guerrero | 5218 | 351 | 711 | 2933 | 1684 | 86 | 6.8k | |
| Howard A. Austin | 3297 | 740 | 2231 | 1256 | 515 | 41 | 6.0k | |
| Z. John Zhong | 4293 | 134 | 351 | 3375 | 2497 | 22 | 5.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...